Potential Role of Lymphocyte CD44 in Determining Treatment Selection Between Stereotactic Body Radiation Therapy and Surgery for Early-Stage Non-Small Cell Lung Cancer.
Weiwei YanZiyuan RenXi ChenRan ZhangJuncai LvVivek VermaMeng WuDawei ChenJinming YuPublished in: International journal of radiation oncology, biology, physics (2024)
Lymphocyte CD44 may not only be a predictor of SBRT efficacy in this population but also an important biomarker (pending validation by large prospective data) that could better sharpen selection for SBRT versus surgery in ES-NSCLC.
Keyphrases
- radiation therapy
- minimally invasive
- early stage
- coronary artery bypass
- small cell lung cancer
- peripheral blood
- surgical site infection
- locally advanced
- nk cells
- advanced non small cell lung cancer
- big data
- coronary artery disease
- sentinel lymph node
- combination therapy
- epidermal growth factor receptor
- brain metastases
- artificial intelligence
- neoadjuvant chemotherapy
- replacement therapy
- tyrosine kinase